arrow
J

James P. Allison

university of texas system
H指数:157
被引数:11.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Antibodies derived from patient tumors augment response to immune checkpoint blockade in cancer
2025-11-010
PRE
Inhibition of CD38 enzyme activity on engrafted human immune cells enhances NAD+ metabolism and inhibits inflammation in an in-vivo model of xeno-GvHD

在异种GvHD的体内模型中,抑制移植的人体免疫细胞上的CD38酶活性可增强NAD+代谢并抑制炎症。

2025-10-130
OAAI
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy

癌症诱导的神经损伤促进抗PD-1疗法的耐药性

Nature
IF48.5
2025-08-200
OA
Spatial profiling reveals unique immune-transcriptomic features of tertiary lymphoid structures in melanoma
2024-03-220
PRE
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

nivolumab联合依鲁替尼治疗CLL弥漫性大b细胞里氏转化患者的2期研究

2023-05-1039
OAAI
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

新辅助化疗联合nivolumab加或不加ipilimumab治疗可手术非小细胞肺癌: 2期平台NEOSTAR试验

2023-03-1694
OAAI
TNB-738, a biparatopic antibody, boosts intracellular NAD plus by inhibiting CD38 ecto-enzyme activity

双互补位抗体TNB-738通过抑制CD38胞外酶活性来增强细胞内NAD plus

MABS
IF7.3
2022-07-2213
OAAI
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy

抗血管生成治疗进展后,sitratinib和nivolumab在透明细胞肾细胞癌中的1-2期试验

2022-04-2041
PRE
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

围手术期nivolumab单药治疗与nivolumab联合ipilimumab治疗可切除肝细胞癌: 一项随机,开放标签,2期试验

2022-03-01158
OAAI